Who
William W. Brooke
Director
Company insider
Files Form 4 as: Director, MaxCyte; Insider, Nuo Therapeutics.
In numbers
- Trades disclosed
- 24
- Buys
- 1
- Sells
- 10
- Bought
- $65K
- Sold
- $246K
- Companies
- 2
- Companies where not an officer
- 2
- First trade
- 13 Jun 2013
- Last trade
- 17 Jun 2026
- Last filed
- 22 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 17 Jun 2026filed 22 Jun 2026 | MXCT MaxCyteLife-science tools | SEC FORM 4 Code A | —30,421 at $0.00 | filing |
| 17 Jun 2026filed 22 Jun 2026 | MXCT MaxCyteoption or derivative · Life-science tools | SEC FORM 4 Code A | —49,579 at $0.00 | filing |
| 17 Jun 2026filed 22 Jun 2026 | MXCT MaxCyteoption or derivative · Life-science tools | SEC FORM 4 Code A | —49,579 at $0.00 | filing |
| 17 Jun 2026filed 22 Jun 2026 | MXCT MaxCyteLife-science tools | SEC FORM 4 Code A | —30,421 at $0.00 | filing |
| 13 Aug 2025filed 13 Aug 2025 | MXCT MaxCyteLife-science tools | SEC FORM 4 Bought | $65K50,000 at $1.29 | filing |
| 18 Jun 2025filed 23 Jun 2025 | MXCT MaxCyteoption or derivative · Life-science tools | SEC FORM 4 Code A | —50,790 at $0.00 | filing |
| 18 Jun 2025filed 23 Jun 2025 | MXCT MaxCyteLife-science tools | SEC FORM 4 Code A | —29,210 at $0.00 | filing |
| 11 Jun 2024filed 13 Jun 2024 | MXCT MaxCyteoption or derivative · Life-science tools | SEC FORM 4 Code A | —40,701 at $0.00 | filing |
| 11 Jun 2024filed 13 Jun 2024 | MXCT MaxCyteLife-science tools | SEC FORM 4 Code A | —21,367 at $0.00 | filing |
| 22 Jun 2023filed 23 Jun 2023 | MXCT MaxCyteoption or derivative · Life-science tools | SEC FORM 4 Code A | —50,000 at $0.00 | filing |
| 29 Jun 2022filed 8 Jul 2022 | MXCT MaxCyteoption or derivative · Life-science tools | SEC FORM 4 Code A | —26,900 at $0.00 | filing |
| 9 Aug 2021filed 11 Aug 2021 | MXCT MaxCyteoption or derivative · Life-science tools | SEC FORM 4 Code A | —10,000 at $0.00 | filing |
| 14 Jan 2015filed 15 Jan 2015 | Nuo Therapeutics | SEC FORM 4 Sold | $54K153,467 at $0.35 | filing |
| 13 Jan 2015filed 15 Jan 2015 | Nuo Therapeutics | SEC FORM 4 Sold | $4,90014,000 at $0.35 | filing |
| 12 Jan 2015filed 12 Jan 2015 | Nuo Therapeutics | SEC FORM 4 Sold | $26K73,496 at $0.35 | filing |
| 9 Jan 2015filed 12 Mar 2015 | Nuo Therapeutics | SEC FORM 4 Sold | $5,54815,850 at $0.35 | filing |
| 9 Jan 2015filed 12 Jan 2015 | Nuo Therapeutics | SEC FORM 4 Sold | $21K61,037 at $0.35 | filing |
| 8 Jan 2015filed 12 Jan 2015 | Nuo Therapeutics | SEC FORM 4 Sold | $29K82,850 at $0.35 | filing |
| 31 Dec 2014filed 2 Jan 2015 | Nuo Therapeutics | SEC FORM 4 Sold | $35100 at $0.35 | filing |
| 30 Dec 2014filed 12 Mar 2015 | Nuo Therapeutics | SEC FORM 4 Sold | $4201,200 at $0.35 | filing |
News
MaxCyte Sees Preliminary Q3 Core Revenue Of About $8.1 Mln, Raises FY26 Guidance; Shares UpMXCT · rttnews.com · 14 Oct 2026MaxCyte Reports Preliminary Third Quarter 2026 Revenue and Raises Full Year 2026 Revenue GuidanceMXCT · manilatimes.net · 14 Oct 2026
0 headlines in the last 90 days name William W. Brooke; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.